Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eurofins Scientific SEERFSF -2.79%76 EV-to-OCF is 10.83 as of Jul. 20, 2026, which is 32% below its 10-year median of 15.93. GuruFocus rates ERFSF with a GF Score™ of 76/100 and a GF Value™ of $78.19 (Fairly Valued). The stock has 7 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 62.91% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Eurofins Scientific SE's Enterprise Value is $17,635 Mil.
Eurofins Scientific SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $1,629 Mil. Therefore, Eurofins Scientific SE's EV-to-OCF for today is 10.83.
The historical rank and industry rank for Eurofins Scientific SE's EV-to-OCF or its related term are showing as below:
ERFSF'
s EV-to-OCF Range Over the Past 10 Years
Min: 9.25 Med: 15.93 Max: 27.66
Current: 10.83
During the past 13 years, the highest EV-to-OCF of Eurofins Scientific SE was 27.66. The lowest was 9.25. And the median was 15.93.
ERFSF's EV-to-OCF is ranked worse than 62.91% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.18
vs ERFSF: 10.83
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eurofins Scientific SE (OTCPK:ERFSF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eurofins Scientific SE's PE Ratio (TTM) for today is calculated as:
Eurofins Scientific SE's share price for today is $78.73.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eurofins Scientific SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $2.963.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's EV-to-OCF falls into.
Eurofins Scientific SE's current Enterprise Value is $17,635 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eurofins Scientific SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $1,629 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a EV-to-OCF of 10.83 as of Jul. 20, 2026. This is 32% below median its historical median of 15.93. Over the past decade, Eurofins Scientific SE's EV-to-OCF has ranged from 9.25 to 27.66. According to the industry distribution chart, Eurofins Scientific SE ranks #134 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 62.9%.
Is Eurofins Scientific SE's EV-to-OCF too high?
Eurofins Scientific SE's current EV-to-OCF of 10.83 is 32% below median its 10-year median of 15.93. Over the past 10 years, this metric has ranged from a low of 9.25 to a high of 27.66. The Medical Diagnostics & Research industry median EV-to-OCF is 6.18. Eurofins Scientific SE's value of 10.83 is 75.2% above this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #134 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #134 out of 213 companies for EV-to-OCF. This places Eurofins Scientific SE in the lower half of its industry. The industry median EV-to-OCF is 6.18. Eurofins Scientific SE's value of 10.83 is 75.2% above this benchmark. Historically, Eurofins Scientific SE's own EV-to-OCF has ranged from 9.25 to 27.66 over the past decade. While the company's 10-year median is 15.93 vs. the industry median of 6.18, Eurofins Scientific SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.18, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current EV-to-OCF of 10.83 is 75.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current EV-to-OCF is 10.83, which is 32% below median its own 10-year median of 15.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $78.19, compared to a current price of $78.73 — trading 0.7% above its estimated fair value. The current EV-to-OCF is 10.83, which is 32% below median its 10-year median of 15.93 and 75.2% above the Medical Diagnostics & Research industry median of 6.18. Eurofins Scientific SE's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current EV-to-OCF is 10.83 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $78.73 is trading 0.7% above its estimated GF Value™ of $78.19.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
EV-to-OCF: 10.83 (32% below median its 10-year median of 15.93)
GF Value™: $78.19 vs. price of $78.73 (0.7% above fair value)
Industry Position: 75.2% above the Medical Diagnostics & Research median (#134 of 213)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
76GF Score
Get the complete analysis for ERFSF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
